NCT00087568View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

PHASE4CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Ribavirin

1000/1200mg po bid for 36 or 60 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)

Trial Locations (25)

10032

New York

10595

Valhalla

11030

Manhasset

11219

Brooklyn

11358

Bayside

21229

Baltimore

21401

Annapolis

22031

Fairfax

23298

Richmond

28677

Statesville

30106

Austell

32806

Orlando

34209

Bradenton

37920

Knoxville

38120

Memphis

45219

Cincinnati

64131

Kansas City

77054

Houston

91105

Pasadena

92123

San Diego

93301

Bakersfield

94403

San Mateo

98405

Tacoma

33136-1051

Miami

02114

Boston

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00087568 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin | Biotech Hunter | Biotech Hunter